New drug TESP-0401 enters first human safety tests

NCT ID NCT07658638

Recruiting now Knowledge-focused Sponsor: Tes Pharma S.r.l. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 6 times

Summary

This early-stage study tests the safety of a new drug, TESP-0401, in 68 healthy volunteers. Participants receive either the drug or a placebo as a single dose or daily for 7 days. Researchers will monitor side effects and measure how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TESP-0401
What could go wrong: This is an early phase 1 study in healthy people, so it only tests safety and drug processing—not whether it works for any disease. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Novatrials
RECRUITING

Charlestown, Suite 301, 99 Pacific Highway,NSW, 2290, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.